Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

IntroductionApproximately 40% of patients with uveal melanoma (UM) will develop metastatic disease. Tumors measuring at least 12mm in basal diameter with a class 2 signature, as defined by a widely used gene expression-profiling test, are associated with significantly higher risk of metastasis, with...

Full description

Bibliographic Details
Main Authors: Shaheer Khan, Jose Lutzky, Alexander N. Shoushtari, Joanne Jeter, Brian Marr, Thomas E. Olencki, Colleen M. Cebulla, Mohamed Abdel-Rahman, J. William Harbour, Naomi Sender, Alexandra Nesson, Shahnaz Singh-Kandah, Susana Hernandez, Jeanelle King, Manpreet S. Katari, Lyssa Dimapanat, Stephanie Izard, Grazia Ambrosini, Oliver Surriga, Alex J. Rai, Codruta Chiuzan, Gary K. Schwartz, Richard D. Carvajal
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
uveal melanoma
high-risk
adjuvant therapy
crizotinib
extracellular vesicles
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.976837/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.976837/full

Similar Items